Voydeya (Danicopan)
Voydeya (Danicopan)
- Medicine Name: Voydeya
- API: Danicopan
- Dosage Form & Strength: Tablets: 50 mg and 100 mg
- Manufactured By: Alexion, AstraZeneca
Voydeya (danicopan) is a complement factor D inhibitor used as add-on therapy to ravulizumab or eculizumab for the treatment of extravascular hemolysis (EVH) in adults with paroxysmal nocturnal hemoglobinuria (PNH).
Limitations of Use: This therapeutic drug has not been shown to be effective as monotherapy and should only be prescribed as an add-on to ravulizumab or eculizumab.
Recommended Dosage: The recommended dosage is 150 mg three times a day administered orally. This medicine can be taken with or without food. The dosage can be increased to 200 mg three times daily if the patient’s hemoglobin (Hgb) level has not increased by greater than 2 g/dL after 4 weeks of therapy, if the patient needs a transfusion during the previous 4 weeks, or to achieve an appropriate Hgb response on behalf of clinical judgment.
A patient who misses a dose should take it as quickly as they remember unless it is within 3 hours before their next scheduled dose, in which case the patient should skip the missed dose and take the medicinal product at the next regularly scheduled time. It is not advisable to take two or more doses at the same time.
- Hepatic enzyme elevations may occur in patients treated with Danicopan. Assess liver enzyme test results before initiating Danicopan and periodically during treatment. Treatment can be interrupted or discontinued if elevations are clinically significant or if the patient becomes symptomatic
- After stopping treatment with Voydeya 50 mg/100 mg, closely monitor patients for at least 2 weeks after the final dose for signs and symptoms of hemolysis. If discontinuation of therapy is necessary, continue background treatment with ravulizumab/eculizumab or consider alternative therapy if required.
- This therapeutic drug increases total cholesterol and LDL-cholesterol. Monitor serum lipid parameters periodically during treatment with Danicopan and initiate cholesterol-lowering medication, if indicated. Cholesterol-lowering medications can be used in some patients.
- The safety of danicopan during pregnancy and lactation has not been established. It should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Nursing mothers should discontinue breastfeeding or discontinue the drug, considering the importance of the drug to the mother.
- Voydeya 100 mg/50 mg may interact with other medications. Patients should inform their healthcare provider of all medications they are taking, including over-the-counter drugs and supplements, to avoid potential interactions.
- Patients should be up to date with all vaccinations before initiating treatment with danicopan. Live vaccines should be avoided during treatment.
What documents are required to import VOYDEYA to India?
VOYDEYA (danicopan) tablets can be imported by patients or government hospitals in the name of the patients only.
The following documentation is required to import the product:
- A valid prescription from a qualified doctor.
- Patients diagnostic reports
- Patient ID proof (issued by the government of India)
The order will be confirmed only after the receipt of:
- A valid prescription from the Doctor
- Import permit if applicable
- Is VOYDEYA available in India?
IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator providing input
- On availability of Voydeya in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune etc.)
- Medicine Price.
- Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
- Ensuring 100% transparency.
IPN (Indian Pharma Network) can facilitate the supply of VOYDEYA (prescription medicines) to all locations in the world and India after fulfilling the legal requirement (if applicable).
Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Voydeya tablet price in India.
We guarantee quality and delivery anywhere in the world as per the buyer’s requirements.
Indian Pharma Network can source the VOYDEYA (Cancer Treatment Medicines) from across the globe and can supply. Indian Pharma offers its customers worldwide access to the best available treatment.
Indian Pharma Network (IPN) can dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.
What is the Generic Name for the trade name drug Voydeya®?
Danicopan is a Generic Name for the trade name drug Voydeya®.
What is the Manufacturer’s Name of Voydeya®?
Voydeya® is manufactured by Alexion Pharmaceuticals, Inc, (AstraZeneca).
Is Voydeya® approved by the FDA?
Yes, Voydeya® is approved by the FDA. Date of first approval: March 29, 2024.
What is the dosage and form of Voydeya® supplied?
Voydeya® is supplied as Tablets: 50 mg and 100 mg for oral administration.
What are the most common side effects of Voydeya®?
The most common side effect of Voydeya® is headache.
How much does Voydeya® cost in India?
Prices may fluctuate over time due to market dynamics and regulatory changes. To obtain accurate and up-to-date information on the cost of Voydeya tablets in India, it is recommended to Call/WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.
What are the storage conditions of Voydeya®?
Store and dispense the medicine in the original container at 20-25°C (68-77°F) with excursions permitted between 15°C and 30°C (59°F and 86°F).
Is it safe to buy Voydeya® online in India?
Yes, one can buy Voydeya online in India at the lowest price from the Indian Pharma Network (IPN) if this medicinal product is not (yet) registered or available in their country. We can help facilitate the supply of Voydeya® through legal channels.
Contact Patient Support
If you have any questions or need any help, contact our Patient Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
Disclaimer
All Trademarks and Brands that appear on the website belong to their respective owners and indianpharmanetwork does not lay any claim on them we only provide Information.